ORTHOCELL ANNOUNCES FIRST US REMPLIR SALES REVENUE:

- Orthocell ha recorded its first US sales revenue from its flagship Remplir product.

- Revenue follows first surgical use of Remplir on June 25 in Ohio and subsequent early surgical cases in Florida sourced from the Company’s network of specialist distributors.

- Orthocell has transitioned from receipt of US FDA 510(k) clearance for Remplir to first revenue generation in just over 3 months.

- Early-stage surgeries conducted in out-patient day surgeries, known as Ambulatory Surgical Centers in the US, play a crucial strategic role in building experience and knowledge amongst the US surgical community in the significant US$1.6 Billion US market.

- Order fulfillment and associated customer invoicing workflow validated.

- Remplir US inventory held and shipped to customers by on-the-ground logistics partner Uniphar.

CEO/MD Paul Anderson: “We are confident our efforts in the US are on track to drive growth in sales of Remplir during the second half of calendar 2025.”

We shall see.

Held IRL